SELL one-third of MDLZ exposure over two to four weeks at market, with hard stop on residual at $65.50; do not redeploy trimmed capital into equities; park in short-duration investment-grade fixed income or T-bills; maintain dividend capture on residual two-thirds; if price closes below $61 on rising volume with RSI breaking 40, exit residual entirely.

• One-third trim over two to four weeks into $64 to $65 zone is appropriate sizing given technical deterioration with stretched 18.55x forward multiple
• Stop on residual must move from $66.65 to $65.50 to avoid being bought back in at 52-week high if stopped out
• Trimmed capital should NOT be redeployed into equities; park in cash equivalents, short-duration IG bonds, or T-bills yielding north of 4%
• Execution timing should not wait for strength toward $64 to $65; trim regardless if tape deteriorates to $60
• Dividend is real cash flow: 3.33% yield, $2.65 billion annual payout, 7.8% CAGR from $1.985B FY22 to $2.487B FY25
• MDLZ is a defensive compounder with 70%+ non-USD revenue providing currency diversification
• Fair value estimate: $62 base case, $72 to $75 bull case, $52 to $55 bear case (roughly symmetric, not 2.5 to 1)
• Q1'26 showed revenue plus 8.3% YoY and operating income plus 26% YoY, not bear-case fundamentals
• Technical setup: price below 10 EMA at $63.21, MACD histogram negative at -0.11, failed upper Bollinger tag at $64.75, RSI cooling from overbought to neutral
• Beta of 0.40 means momentum shifts in this low-beta name are more reliable, not less
• If price closes below $61 on rising volume with RSI breaking 40, exit residual rather than waiting for $58 dip entry

→ vs aggressive: Redeploying trimmed capital into 'lower-multiple staples peers' or 'broader market rotation' just rotates risk rather than reduces it; cash is a position

→ vs aggressive: Stop placement at $66.65 is the 52-week high; if stopped out, the residual gets bought back at a higher price than where the trim was sold, creating asymmetric payoff in the wrong direction

→ vs aggressive: Framing dividend as 'compensation for risk' and 'sales pitch' is intellectually dishonest; $2.65B annual cash payout is real, growing, contractual cash flow

→ vs aggressive: 2.5 to 1 downside risk-reward claim is asserted but not demonstrated; fair value range is roughly symmetric around $62, not 2.5 to 1 against

→ vs aggressive: Aggressive analyst is letting technicals drive fundamentals view, which is backwards; fundamentals determine where stock ends up, technicals are just timing tool

→ vs neutral: 'Wait for Q3 earnings' means holding through two more months of unresolved input cost risk, FX risk, and tape already telegraphing deterioration; 'accumulate on weakness toward $58' is catching a falling knife if price drops to $58

→ vs neutral: Innovation pipeline framing (Grenade US, Oreo flavor rotations, Tate's premium) overpays for innovation optionality that doesn't break the 3-5% organic growth profile

→ vs neutral: Neutral is calling momentum loss 'consolidation'; in a 0.40 beta name, momentum shifts are more reliable, not less, due to reduced noise from broad market correlation

Sell one-third of MDLZ exposure over 2-4 weeks (60% at $64-$65 zone, 40% at market); residual stop at $65.85; park trimmed capital in short-duration IG fixed income/T-bills with staged redeployment over 4-8 weeks; maintain dividend capture on residual; exit residual on close below $61 with rising volume and RSI below 40; reassess after Q3 earnings in mid-October; do not initiate new longs.

• Forward PE of 18.55x embeds 23% EPS recovery versus a 3-5% structural growth profile
• MDLZ dividends grew from $1.985 billion in 2022 to $2.487 billion in 2025 (7.8% CAGR)
• 70% non-USD revenue base provides partial dollar hedge
• Q1'26 revenue +8.3% YoY, operating income +26% YoY
• Base case around $62, bull case $72-$75, bear case $52-$55 (roughly symmetric, not 2.5-to-1 risk-reward)
• Consensus EPS of $3.36 is aggressive per Q3 outlook
• Golden cross confirmed mid-July; 200 SMA rising; long-term trend structure intact
• Failed upper Bollinger tag at $64.75; price below 10 EMA; negative MACD histogram; RSI cooling
• 14-day ATR of $1.36; proposed stop at $65.85 (daily close) is approximately 1.1-1.3x ATR
• Grenade US launch provides exposure to high-protein snacking secular trend
• Tate's premium cookies driving real mix lift in biscuits
• Buyback pause at YTD highs is a structural bear signal

→ vs aggressive: Risk-reward of 2.5-to-1 is asserted, not demonstrated; base/bull/bear cases are roughly symmetric around current price

→ vs aggressive: Calling dividend a 'sales pitch' ignores 7.8% CAGR dividend growth and currency diversification from 70% non-USD revenue

→ vs aggressive: Dismissal of innovation pipeline is too reductive; Grenade and Tate's are not zero, just insufficient alone to justify multiple

→ vs aggressive: Immediate redeployment into equities relocates risk rather than reducing it; should be staged with high-conviction setups only

→ vs conservative: Stop at $66.65 creates asymmetric outcome: forced repurchase at 52-week high if stock rallies through that level

→ vs conservative: Stop at $65.50 is too tight (1.1x ATR); will get whipsawed by routine noise in a low-beta name

→ vs conservative: 'Trim regardless of price' is mechanically rigid; selling into weakness when price drops to $60 is reactive, not conservative

→ vs conservative: Indefinite T-bill parking is overcorrection; capital should be staged for redeployment if high-conviction setups emerge in 4-8 weeks

→ vs conservative: Defending dividend as bull-case signal while bearish on multiple is partially inconsistent; dividend exists in both bull and bear scenarios